Barings LLC Reduces Stock Holdings in Qiagen N.V. (NYSE:QGEN)

Key Points

• Barings LLC has reduced its stake in Qiagen N.V. by 1.7%, owning approximately 0.18% of the company, valued at $16.2 million after selling shares during the first quarter.
• During its latest quarter, Qiagen reported earnings per share of $0.55, exceeding analyst expectations of $0.50, with revenue of $483.46 million, marking a 5.2% increase year-over-year.
• The company recently declared a dividend of $0.25 per share, leading to a dividend yield of 52.0% and a payout ratio of 62.50%.

Barings LLC trimmed its holdings in Qiagen N.V. (NYSE:QGEN - Free Report) by 1.7% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 407,996 shares of the company's stock after selling 6,988 shares during the period. Barings LLC owned approximately 0.18% of Qiagen worth $16,195,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. ANTIPODES PARTNERS Ltd bought a new stake in shares of Qiagen during the 1st quarter worth $94,000. Tower Research Capital LLC TRC lifted its stake in Qiagen by 770.6% in the fourth quarter. Tower Research Capital LLC TRC now owns 2,490 shares of the company's stock worth $111,000 after purchasing an additional 2,204 shares during the last quarter. GAMMA Investing LLC lifted its stake in Qiagen by 93.9% in the first quarter. GAMMA Investing LLC now owns 2,943 shares of the company's stock worth $118,000 after purchasing an additional 1,425 shares during the last quarter. Federated Hermes Inc. bought a new stake in Qiagen in the first quarter worth $150,000. Finally, Wealth Enhancement Advisory Services LLC bought a new stake in Qiagen in the fourth quarter worth $202,000. 70.00% of the stock is currently owned by hedge funds and other institutional investors.

Qiagen Trading Down 0.7%

Shares of QGEN stock traded down $0.34 during trading hours on Tuesday, reaching $49.91. 2,073,954 shares of the stock were exchanged, compared to its average volume of 1,377,760. The firm has a market capitalization of $11.09 billion, a price-to-earnings ratio of 125.14, a price-to-earnings-growth ratio of 2.54 and a beta of 0.64. The company has a current ratio of 3.37, a quick ratio of 2.83 and a debt-to-equity ratio of 0.40. Qiagen N.V. has a 12-month low of $37.63 and a 12-month high of $51.88. The company's 50-day moving average price is $47.71 and its 200-day moving average price is $43.46.

Qiagen (NYSE:QGEN - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.55 EPS for the quarter, beating the consensus estimate of $0.50 by $0.05. Qiagen had a net margin of 4.68% and a return on equity of 14.61%. The business had revenue of $483.46 million during the quarter, compared to analyst estimates of $465.66 million. During the same quarter in the previous year, the business posted $0.44 EPS. The company's quarterly revenue was up 5.2% compared to the same quarter last year. As a group, equities analysts anticipate that Qiagen N.V. will post 2.26 earnings per share for the current year.

Qiagen Dividend Announcement

The company also recently disclosed a dividend, which was paid on Thursday, July 10th. Investors of record on Thursday, July 3rd were paid a dividend of $0.25 per share. This represents a dividend yield of 52.0%. The ex-dividend date was Wednesday, July 2nd. Qiagen's payout ratio is 62.50%.

Analysts Set New Price Targets

Several analysts have weighed in on the stock. Bank of America boosted their price target on shares of Qiagen from $50.00 to $53.00 and gave the stock a "buy" rating in a research note on Thursday, June 26th. Wall Street Zen upgraded shares of Qiagen from a "buy" rating to a "strong-buy" rating in a research report on Sunday. Robert W. Baird boosted their price target on shares of Qiagen from $42.00 to $43.00 and gave the company a "neutral" rating in a research report on Monday, April 21st. Finally, Barclays assumed coverage on shares of Qiagen in a research report on Tuesday, June 24th. They set an "overweight" rating and a $55.00 price target on the stock. Seven equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $49.40.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.